COMP <GO>
CORT vs CYTK // NET PROFIT MARGIN
Corcept Therapeutics Incorporated (NASDAQ) VS. Cytokinetics Incorporated (NASDAQ) • 15-METRIC TALLY: CORT 8
— CYTK 3
▲ NET PROFIT MARGIN LEADER: CORT
LAST: $80.46 (-0.81%) • MKT CAP: $8.77B
net-margins
13.10%
LAST: $62.03 (-1.52%) • MKT CAP: $8.76B
net-margins
-60.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CORT VS. CYTK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CORT | CYTK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.80% | -35.00% | +39.80 | CORT | /roic <GO> |
| EV/EBITDA & P/E Valuation | 95.0x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 1.53% | -6.08% | +7.61 | CORT | /fcf-yield <GO> |
| Operating Margin | 5.90% | -60.00% | +65.90 | CORT | /operating-margins <GO> |
| Net Profit Margin ACTIVE | 13.10% | -60.00% | +73.10 | CORT | /net-margins <GO> |
| Revenue Growth (YoY) | 12.80% | 180.00% | -167.20 | CYTK | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 0.45 | +25.55 | CORT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 5/9 | +3.00 | CORT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 27.6 | 46.0 | -18.40 | CYTK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | 0.87 | +0.01 | CORT | /macro-sensitivity <GO> |
| Forward P/E Multiple | 78.3x | 31.0x | +47.30 | CYTK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $8.77B | $8.76B | $11.9M | CORT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CORT REV | CYTK REV | CORT GROSS % | CYTK GROSS % | CORT FCF | CYTK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $761.4M | $88.0M | 98.3% | — | $141.8M | -$534.8M |
| FY 2024 | $675.0M | $18.5M | 98.4% | — | $196.1M | -$399.8M |
| FY 2023 | $482.4M | $7.5M | — | — | $105.0M | -$414.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CORT // BETA 0.88
CYTK // BETA 0.87